EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines

Alpay Ari, Zeynep Altinay, Didem Demircan

The Journal of Infection in Developing Countries · 31.05.2026 · 20 (05) · 637-648

DOI: 10.3855/jidc.21743 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 31.05.2026. Verfasst von Alpay Ari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Provincial Directorate of Health, University of Health Sciences Izmir Bozyaka Education and Research Hospital, Izmir, Türkiye. Hauptthemen laut MEDLINE: Vaccine Efficacy, COVID-19 Vaccines, COVID-19. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study investigates the effectiveness of different coronavirus disease (COVID-19) vaccines in preventing hospitalization, ICU admissions, and mortality in Türkiye, upon comparing the responses to heterologous, inactivated, and mRNA vaccines. Methodology: Data were gathered from 24,538 individuals, aged ≥ 18 years, whose COVID-19 status was confirmed through PCR testing. An analysis of the survival distributions for six vaccine types showed significant differences in severe disease outcomes, with distinct patterns observed for individuals older and younger than 65 years.

Results

Vaccines, including two-dose mRNA, both heterologous and homologous, showed the most protective and durable vaccine effectiveness. Homologous and heterologous inactivated vaccines demonstrated statistically significant reductions in severe COVID-19 outcomes for individuals aged > 65 years compared to unvaccinated individuals.

Conclusions

The results suggest that an early deployment of inactivated vaccines, despite being less advanced, may have played an important role in providing timely protection, mitigating severe outcomes, especially in countries with limited access to novel vaccine technologies. This study provides key insights for shaping future vaccine strategies and public health policies, particularly in regions with varying access to healthcare resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine EfficacyCOVID-19 VaccinesCOVID-19HumansVaccines, InactivatedFemaleAgedSARS-CoV-2Middle AgedMaleAdultVaccines, SyntheticmRNA VaccinesYoung AdultAdolescentHospitalizationPandemics

Stichwörter der Autor:innen

COVID-19pandemicprotective effectivenesspublic healthsevere disease outcomesvaccine strategy

Substanzen

COVID-19 VaccinesVaccines, InactivatedVaccines, SyntheticmRNA Vaccines

Autor:innen und Institutionen

  • Izmir Provincial Directorate of Health, University of Health Sciences Izmir Bozyaka Education and Research Hospital, Izmir, Türkiye.
  • University of Nevada-Reno, Reno, NV, United States.

Zitieren

APA

Ari, A., Altinay, Z., & Demircan, D. (2026). Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines. The Journal of Infection in Developing Countries, 20(05), 637-648. https://doi.org/10.3855/jidc.21743

Vancouver

Ari A, Altinay Z, Demircan D. Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines. The Journal of Infection in Developing Countries. 2026;20(05):637-648. doi:10.3855/jidc.21743

BibTeX
@article{Ari2026,
  author = {Ari, Alpay and Altinay, Zeynep and Demircan, Didem},
  title = {Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines},
  journal = {The Journal of Infection in Developing Countries},
  year = {2026},
  volume = {20},
  number = {05},
  pages = {637--648},
  doi = {10.3855/jidc.21743}
}
Kostenlos starten →